NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month Low - Here's What Happened

Key Points

• NewAmsterdam Pharma shares fell 8.7% to a new 52-week low of $19.13, with the stock last trading at $19.71 and well below its 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive despite the selloff: the stock has a consensus “Moderate Buy” rating and an average price target of $48.90, though ratings range from “Strong Buy” to “Sell.”
• The company reported a quarterly EPS loss of $0.52, missing estimates, while revenue of $3.70 million exceeded expectations. NewAmsterdam remains a clinical-stage biotech focused on late-stage trials of obicetrapib, a cholesterol-lowering therapy.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) hit a new 52-week low during mid-day trading on Saturday. The stock traded as low as $19.13 and last traded at $19.71, with a volume of 2,311,178 shares trading hands. The stock had previously closed at $21.58.

Wall Street Analyst Weigh In

Several brokerages have weighed in on NAMS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. HC Wainwright reiterated a "buy" rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an "outperform" rating and a $58.00 target price on the stock. Royal Bank Of Canada lowered their target price on NewAmsterdam Pharma from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, October 5th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, NewAmsterdam Pharma presently has a consensus rating of "Moderate Buy" and an average target price of $48.90.

NewAmsterdam Pharma Stock Down 8.7%

The business has a fifty day moving average of $23.54 and a 200 day moving average of $29.21. The firm has a market cap of $2.36 billion, a P/E ratio of -9.12 and a beta of 0.10.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. On average, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michael H. Davidson acquired 10,000 shares of the company's stock in a transaction on Monday, September 14th. The stock was purchased at an average cost of $22.65 per share, with a total value of $226,500.00. Following the acquisition, the chief executive officer directly owned 792,923 shares of the company's stock, valued at approximately $17,959,705.95. The trade was a 1.28% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johannes Kastelein sold 50,246 shares of the company's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.03, for a total value of $1,257,657.38. Following the sale, the insider owned 69,302 shares of the company's stock, valued at approximately $1,734,629.06. The trade was a 42.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 176,846 shares of company stock worth $4,661,919 in the last quarter. 12.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NAMS. Engineers Gate Manager LP acquired a new stake in NewAmsterdam Pharma in the second quarter valued at about $662,000. Squarepoint Ops LLC grew its holdings in shares of NewAmsterdam Pharma by 113.9% during the 2nd quarter. Squarepoint Ops LLC now owns 92,026 shares of the company's stock valued at $3,119,000 after purchasing an additional 49,005 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of NewAmsterdam Pharma by 34.6% during the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company's stock valued at $564,000 after purchasing an additional 4,281 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company's stock worth $613,033,000 after purchasing an additional 1,145,128 shares in the last quarter. Finally, Bank of America Corp DE increased its position in NewAmsterdam Pharma by 84.4% during the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company's stock worth $27,115,000 after purchasing an additional 387,698 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma NASDAQ: NAMS is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company's primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.